Contract award notice
Results of the procurement procedure
Section I: Contracting
entity
I.1) Name and addresses
CELL AND GENE THERAPY CATAPULT
10016023
12TH FLOOR TOWER WING,GUY'S HOSPITAL, GREAT MAZE POND
LONDON
SE19RT
UK
E-mail: procurement@ct.catapult.org.uk
NUTS: UKI44
Internet address(es)
Main address: https://ct.catapult.org.uk/
I.4) Type of the contracting authority
Body governed by public law
I.5) Main activity
Health
Section II: Object
II.1) Scope of the procurement
II.1.1) Title
Ribosome profiling of suspension-adapted HEK293 cells producing adeno-associated viruses
II.1.2) Main CPV code
73111000
II.1.3) Type of contract
Services
II.1.4) Short description
Services for the ribosome profiling of suspension-adapted human cells producing an adeno-associated virus (AAV) vector.Human cells will be subjected to AAV production in parallel with controls. A range of samples (between 21 and 35) will be generated in this experiment, designated as "Run 1". The samples will then be processed by the awarded Bidder. In addition to "Run 1", two additional runs ("Run 2" and "Run 3") may be performed at our sole discretion. Importantly, the experimental setup for both "Run 2" and "Run 3" will be similar to that for "Run 1", but sample numbers may differ if additional conditions are included or excluded. A maximum of 35 samples will be obtained for either "Run 2" and "Run 3".
II.1.6) Information about lots
This contract is divided into lots:
No
II.1.7) Total value of the procurement
Value excluding VAT:
252 000.00
GBP
II.2) Description
II.2.2) Additional CPV code(s)
73100000
II.2.3) Place of performance
NUTS code:
UKI
II.2.4) Description of the procurement
Services for the ribosome profiling of suspension-adapted human cells producing an adeno-associated virus (AAV) vector.Human cells will be subjected to AAV production in parallel with controls. A range of samples (between 21 and 35) will be generated in this experiment, designated as "Run 1". The samples will then be processed by the awarded Bidder. In addition to "Run 1", two additional runs ("Run 2" and "Run 3") may be performed at our sole discretion. Importantly, the experimental setup for both "Run 2" and "Run 3" will be similar to that for "Run 1", but sample numbers may differ if additional conditions are included or excluded. A maximum of 35 samples will be obtained for either "Run 2" and "Run 3".
II.2.5) Award criteria
Quality criterion: Quality
/ Weighting: 60%
Cost criterion: Pricing Schedule
/ Weighting: 40%
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Section IV: Procedure
IV.1) Description
IV.1.1) Type of procedure
Open procedure
IV.1.8) Information about Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement:
Yes
IV.2) Administrative information
IV.2.1) Previous publication concerning this procedure
Notice number in the OJ S:
2022/S 000-018191
Section V: Award of contract
A contract/lot is awarded:
Yes
V.2 Award of contract
V.2.1) Date of conclusion of the contract
13/09/2022
V.2.2) Information about tenders
Number of tenders received: 2
The contract has been awarded to a group of economic operators:
No
V.2.3) Name and address of the contractor
EIRNA Bio Ltd.
604732
Cork, Ireland
UK
NUTS: UK
The contractor is an SME:
Yes
V.2.4) Information on value of the contract/lot (excluding VAT)
Total value of the contract/lot:
: 252 000.00
GBP
V.2.5) Information about subcontracting
Section VI: Complementary information
VI.4) Procedures for review
VI.4.1) Review body
Cell and Gene Therapy Catapult
London
UK
VI.5) Date of dispatch of this notice
13/09/2022